FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040219306> ?p ?o ?g. }

• W2040219306 endingPage "1964.e3" @default.
• W2040219306 startingPage "1957" @default.
• W2040219306 abstract "Purpose To evaluate the effect of intravitreal ranibizumab on retinal capillary hemangioblastomas (RCHs) associated with von Hippel-Lindau (VHL) disease that are not amenable or responsive to standard therapy. Design Prospective, noncomparative, interventional case series. Participants Five patients with VHL-associated RCH with exudative changes and visual loss. Methods Monthly intravitreal injections of ranibizumab (0.5 mg) were given over a course of 6 months for a total of 7 injections, with additional injections considered until week 52. The final study visit was designated as 8 weeks after the final study injection. Main Outcome Measures The primary outcome was the change in best-corrected visual acuity (BCVA) of ≥15 letters at the final visit compared with baseline. Secondary outcomes included change in lesion size, exudation as assessed clinically and by fluorescein angiography, change in retinal thickness as evaluated by optical coherence tomography, and adverse event assessments. Results Patients received an average of 10.0±3.1 injections over an average period of 47±14 weeks, including follow-up. Mean change in BCVA was a decrease of 9±20 letters, with 1 patient gaining ≥15 letters, and 2 patients losing ≥15 letters. Changes in both lesion size and exudation were variable. Conclusions Intravitreal ranibizumab, delivered as monotherapy every 4 weeks, had minimal beneficial effects on most VHL-related RCHs. Possible treatment efficacy was demonstrated in the patient with the smallest lesion with less exudation. Future prospective studies are needed to determine the potential role of an antiangiogenic agent, possibly in combination with other therapies for the treatment of such advanced ocular tumors associated with VHL. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article. To evaluate the effect of intravitreal ranibizumab on retinal capillary hemangioblastomas (RCHs) associated with von Hippel-Lindau (VHL) disease that are not amenable or responsive to standard therapy. Prospective, noncomparative, interventional case series. Five patients with VHL-associated RCH with exudative changes and visual loss. Monthly intravitreal injections of ranibizumab (0.5 mg) were given over a course of 6 months for a total of 7 injections, with additional injections considered until week 52. The final study visit was designated as 8 weeks after the final study injection. The primary outcome was the change in best-corrected visual acuity (BCVA) of ≥15 letters at the final visit compared with baseline. Secondary outcomes included change in lesion size, exudation as assessed clinically and by fluorescein angiography, change in retinal thickness as evaluated by optical coherence tomography, and adverse event assessments. Patients received an average of 10.0±3.1 injections over an average period of 47±14 weeks, including follow-up. Mean change in BCVA was a decrease of 9±20 letters, with 1 patient gaining ≥15 letters, and 2 patients losing ≥15 letters. Changes in both lesion size and exudation were variable. Intravitreal ranibizumab, delivered as monotherapy every 4 weeks, had minimal beneficial effects on most VHL-related RCHs. Possible treatment efficacy was demonstrated in the patient with the smallest lesion with less exudation. Future prospective studies are needed to determine the potential role of an antiangiogenic agent, possibly in combination with other therapies for the treatment of such advanced ocular tumors associated with VHL." @default.
• W2040219306 created "2016-06-24" @default.
• W2040219306 creator A5004857974 @default.
• W2040219306 creator A5020378021 @default.
• W2040219306 creator A5039958951 @default.
• W2040219306 creator A5041500763 @default.
• W2040219306 creator A5090802305 @default.
• W2040219306 date "2008-11-01" @default.
• W2040219306 modified "2023-10-01" @default.
• W2040219306 title "Intravitreal Ranibizumab Therapy for Retinal Capillary Hemangioblastoma Related to von Hippel-Lindau Disease" @default.
• W2040219306 cites W1973119859 @default.
• W2040219306 cites W1980013575 @default.
• W2040219306 cites W1981458345 @default.
• W2040219306 cites W1986929568 @default.
• W2040219306 cites W1988651185 @default.
• W2040219306 cites W1992954334 @default.
• W2040219306 cites W2004239325 @default.
• W2040219306 cites W2010646434 @default.
• W2040219306 cites W2017395282 @default.
• W2040219306 cites W2019061836 @default.
• W2040219306 cites W2024307723 @default.
• W2040219306 cites W2035734782 @default.
• W2040219306 cites W2047136006 @default.
• W2040219306 cites W2052164181 @default.
• W2040219306 cites W2060104085 @default.
• W2040219306 cites W2068555261 @default.
• W2040219306 cites W2091407629 @default.
• W2040219306 cites W2093776019 @default.
• W2040219306 cites W2094857036 @default.
• W2040219306 cites W2103772491 @default.
• W2040219306 cites W2108145145 @default.
• W2040219306 cites W2124415048 @default.
• W2040219306 cites W2128073997 @default.
• W2040219306 cites W3023174345 @default.
• W2040219306 doi "https://doi.org/10.1016/j.ophtha.2008.04.033" @default.
• W2040219306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3034164" @default.
• W2040219306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18789534" @default.
• W2040219306 hasPublicationYear "2008" @default.
• W2040219306 type Work @default.
• W2040219306 sameAs 2040219306 @default.
• W2040219306 citedByCount "91" @default.
• W2040219306 countsByYear W20402193062012 @default.
• W2040219306 countsByYear W20402193062013 @default.
• W2040219306 countsByYear W20402193062014 @default.
• W2040219306 countsByYear W20402193062015 @default.
• W2040219306 countsByYear W20402193062016 @default.
• W2040219306 countsByYear W20402193062017 @default.
• W2040219306 countsByYear W20402193062018 @default.
• W2040219306 countsByYear W20402193062019 @default.
• W2040219306 countsByYear W20402193062020 @default.
• W2040219306 countsByYear W20402193062021 @default.
• W2040219306 countsByYear W20402193062022 @default.
• W2040219306 countsByYear W20402193062023 @default.
• W2040219306 crossrefType "journal-article" @default.
• W2040219306 hasAuthorship W2040219306A5004857974 @default.
• W2040219306 hasAuthorship W2040219306A5020378021 @default.
• W2040219306 hasAuthorship W2040219306A5039958951 @default.
• W2040219306 hasAuthorship W2040219306A5041500763 @default.
• W2040219306 hasAuthorship W2040219306A5090802305 @default.
• W2040219306 hasBestOaLocation W20402193062 @default.
• W2040219306 hasConcept C118487528 @default.
• W2040219306 hasConcept C126322002 @default.
• W2040219306 hasConcept C141071460 @default.
• W2040219306 hasConcept C188816634 @default.
• W2040219306 hasConcept C197934379 @default.
• W2040219306 hasConcept C2776694085 @default.
• W2040219306 hasConcept C2777802072 @default.
• W2040219306 hasConcept C2778257484 @default.
• W2040219306 hasConcept C2778886567 @default.
• W2040219306 hasConcept C2779134260 @default.
• W2040219306 hasConcept C2780248432 @default.
• W2040219306 hasConcept C2780827179 @default.
• W2040219306 hasConcept C2781100027 @default.
• W2040219306 hasConcept C2781156865 @default.
• W2040219306 hasConcept C71924100 @default.
• W2040219306 hasConceptScore W2040219306C118487528 @default.
• W2040219306 hasConceptScore W2040219306C126322002 @default.
• W2040219306 hasConceptScore W2040219306C141071460 @default.
• W2040219306 hasConceptScore W2040219306C188816634 @default.
• W2040219306 hasConceptScore W2040219306C197934379 @default.
• W2040219306 hasConceptScore W2040219306C2776694085 @default.
• W2040219306 hasConceptScore W2040219306C2777802072 @default.
• W2040219306 hasConceptScore W2040219306C2778257484 @default.
• W2040219306 hasConceptScore W2040219306C2778886567 @default.
• W2040219306 hasConceptScore W2040219306C2779134260 @default.
• W2040219306 hasConceptScore W2040219306C2780248432 @default.
• W2040219306 hasConceptScore W2040219306C2780827179 @default.
• W2040219306 hasConceptScore W2040219306C2781100027 @default.
• W2040219306 hasConceptScore W2040219306C2781156865 @default.
• W2040219306 hasConceptScore W2040219306C71924100 @default.
• W2040219306 hasIssue "11" @default.
• W2040219306 hasLocation W20402193061 @default.
• W2040219306 hasLocation W20402193062 @default.
• W2040219306 hasLocation W20402193063 @default.
• W2040219306 hasLocation W20402193064 @default.
• W2040219306 hasOpenAccess W2040219306 @default.
• W2040219306 hasPrimaryLocation W20402193061 @default.
• W2040219306 hasRelatedWork W1593038791 @default.

• next